Rabacfosadine, sold under the brand name Tanovea-CA1, is a

guanine Guanine () (symbol G or Gua) is one of the four main nucleobases found in the nucleic acids DNA and RNA, the others being adenine, cytosine, and thymine ( uracil in RNA). In DNA, guanine is paired with cytosine. The guanine nucleoside is c ...

nucleotide analog Nucleoside analogues are nucleosides which contain a nucleic acid analogue and a sugar. Nucleotide analogs are nucleotides which contain a nucleic acid analogue, a sugar, and a phosphate group with one to three phosphates. Nucleoside and nuc ...

used for the treatment of

lymphoma Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood cell). In current usage the name usually refers to just the cancerous versions rather than all such tumours. Signs and symptoms may include enl ...

in dogs. The drug was granted conditional approval by the

U.S. Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food s ...

under application number 141-475 for use in treating canine lymphoma in December 2016 pending a full demonstration of effectiveness, and became the first drug to receive full approval for the treatment of canine lymphoma in July 2021. Originally developed by

Gilead Sciences Gilead Sciences, Inc. () is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and ...

as GS-9219, rabacfosadine is no longer being pursued for use in the treatment of lymphoma in humans. The active form of rabacfosadine is a chain-terminating inhibitor of the major deoxyribonucleic acid (DNA) polymerases. ''In vitro'' studies have demonstrated that rabacfosadine inhibits DNA synthesis, resulting in S phase arrest and induction of apoptosis. It also inhibits the proliferation of lymphocytes in dogs with naturally occurring lymphoma.

Veterinary uses

In July 2021, the U.S.

Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food ...

(FDA) approved Tanovea to treat lymphoma in dogs. Lymphoma, also called lymphosarcoma, is a type of cancer that can affect many species, including dogs. Tanovea is the first conditionally approved new animal drug for dogs to achieve the FDA's full approval.

Adverse effects

Common side effects of rabacfosadine are decreased white blood cell count, diarrhea, vomiting, decreased appetite or loss of appetite, weight loss, decreased activity level, and skin problems. Other side effects may occur.

References

External links

* {{cite web , url = https://druginfo.nlm.nih.gov/drugportal/name/rabacfosadine , publisher = U.S. National Library of Medicine , work = Drug Information Portal , title = Rabacfosadine Veterinary drugs Purines Cyclopropanes Organophosphates